Why Eli Lilly Stock Climbed Today

Eli Lilly shares jumped 4.86% after the company posted second-quarter revenue of $23 billion, up 48% year-over-year, and adjusted net income of $7.5 billion, both topping Wall Street estimates. The beat was powered by obesity drugs Mounjaro and Zepbound, which recorded sales growth of 91% and 44%, respectively.

Management raised full-year revenue guidance to a range of $85 billion to $87 billion, reflecting confidence in continued demand for its GLP-1 franchise. The company is channeling profits into pipeline expansion through strategic acquisitions, positioning for sustained growth beyond its current blockbuster products.

The quarter underscores Eli Lilly's dominance in the booming weight-loss drug market, where competition with Novo Nordisk remains fierce but demand continues to outpace supply across the category.